RESUMEN
Antecedentes. Un alta diferida es la que se produce cuando, desde el punto de vista clínico, un paciente es dado de alta del hospital, pero continúa ocupando la cama por un problema no médico. Esta circunstancia sobrecarga el sistema sanitario, pero la frecuencia real de la misma y la pérdida de días útiles de hospitalización que ocasiona no han sido evaluadas en nuestro país hasta la fecha. Objetivo. Analizar la demora del alta efectiva por razones no médicas en un Servicio de Medicina Interna de un hospital de tercer nivel y determinar los factores clínicos y sociofamiliares asociados a esta situación. Pacientes y métodos. Estudio observacional y prospectivo, que analizó las características de los pacientes cuya alta se demoró por motivos no médicos durante 12 meses. Resultados. De las 4.850 altas que se produjeron en el Servicio de Medicina Interna, 170 (3,5%) se demoraron por problemas no médicos. Ello supuso una pérdida de 1.603 días útiles para hospitalización de otros enfermos. La mediana de demora fue de 5 días (rango: 3-12 días). Los pacientes con altas diferidas tenían una edad más avanzada, mayor prevalencia de enfermedad cerebrovascular aguda y problemas relacionados con el consumo de alcohol o benzodiacepinas. Los motivos principales aducidos para no irse de alta fueron: la sobrecarga y/o incapacidad de los familiares para el cuidado del enfermo por imposibilidad de conciliar los cuidados que requería con la vida laboral (51,8%), y la carencia de familiares o red de apoyo social (21,8%). Conclusiones. Las altas diferidas por motivos no médicos son frecuentes y están motivadas principalmente por dificultades sociofamiliares para hacerse cargo de los pacientes tras el ingreso hospitalario. Suponen una gran sobrecarga para los hospitales(AU)
Background. Delayed discharge occurs from a clinical point of view when a patient is considered medically fit for discharge but continues occupying a bed due to a nonmedical problem. This circumstance overloads the care system, however, its real frequency and loss of useful days of hospitalization have not being evaluated in Spain up to date. Objective. To analyze the frequency of hospital delayed discharges due to non-medical reasons in a tertiary hospital Internal Medicine Department and to determine the clinical and socio-familial factors related to this situation. Patients and methods. An observational and prospective study was performed to analyze the characteristics of the patients whose discharge was delayed for nonmedical reason over a 12-month period. Results. There were 4850 discharges in the Internal Medicine Department, 170 (3.5%) of which were delayed because of nonmedical problems. This accounted for a loss of 1603 useful days of hospitalization for other patients within one year. The median delay was 5 days (range: 3-12). Patients with delayed discharges were elder and had a higher prevalence of acute cerebrovascular disease as well as alcohol or benzodiazepines use related problems. The main causes were the overload or inability of the family to care for the patient and the impossibility to combine patient care with the family's working life (51.8%), and lack of family or social support network (21.8%). Conclusions. Delayed discharges for nonmedical reasons are frequent and mainly motivated by social-familiar problem to take charge of the patients after their hospitalization. This accounts for a significant overload for the hospitals(AU)
Asunto(s)
Humanos , Masculino , Femenino , Alta del Paciente/estadística & datos numéricos , Alta del Paciente/tendencias , Alta del Paciente/legislación & jurisprudencia , Alta del Paciente/normas , Medicina Interna/métodos , Estudios ProspectivosRESUMEN
BACKGROUND: Delayed discharge occurs from a clinical point of view when a patient is considered medically fit for discharge but continues occupying a bed due to a nonmedical problem. This circumstance overloads the care system, however, its real frequency and loss of useful days of hospitalization have not being evaluated in Spain up to date. OBJECTIVE: To analyze the frequency of hospital delayed discharges due to non-medical reasons in a tertiary hospital Internal Medicine Department and to determine the clinical and socio-familial factors related to this situation. PATIENTS AND METHODS: An observational and prospective study was performed to analyze the characteristics of the patients whose discharge was delayed for nonmedical reason over a 12-month period. RESULTS: There were 4850 discharges in the Internal Medicine Department, 170 (3.5%) of which were delayed because of nonmedical problems. This accounted for a loss of 1603 useful days of hospitalization for other patients within one year. The median delay was 5 days (range: 3-12). Patients with delayed discharges were elder and had a higher prevalence of acute cerebrovascular disease as well as alcohol or benzodiazepines use related problems. The main causes were the overload or inability of the family to care for the patient and the impossibility to combine patient care with the family's working life (51.8%), and lack of family or social support network (21.8%). CONCLUSIONS: Delayed discharges for nonmedical reasons are frequent and mainly motivated by social-familiar problem to take charge of the patients after their hospitalization. This accounts for a significant overload for the hospitals.
Asunto(s)
Tiempo de Internación/estadística & datos numéricos , Alta del Paciente/estadística & datos numéricos , Anciano , Femenino , Departamentos de Hospitales , Humanos , Medicina Interna , Masculino , Estudios Prospectivos , Factores de TiempoRESUMEN
In the study presented here the ribavirin mutagenic effect was investigated by analyzing quasispecies in the viral 5' untranslated region of hepatitis C virus in six patients with chronic infection who started interpheron-alpha and ribavirin therapy. A remarkable mutation rate during treatment was found in only one individual. This patient had a sustained response and harbored a type 3a virus strain. The different mutated clones in this patient demonstrated no apparent close relationship that could suggest lack of selection pressure by ribavirin. The mutations were located within the loops of subdomains IIIb and IIId of the internal ribosomal entry site. This is an interesting initial finding that needs to be substantiated in a larger trial.
Asunto(s)
Regiones no Traducidas 5'/efectos de los fármacos , Hepacivirus/efectos de los fármacos , Hepatitis C Crónica/tratamiento farmacológico , Interferón-alfa/administración & dosificación , Ribavirina/uso terapéutico , Regiones no Traducidas 5'/genética , Quimioterapia Combinada , Hepacivirus/genética , Hepatitis C Crónica/genética , Humanos , Interferón alfa-2 , Interferón-alfa/efectos adversos , ARN Viral/análisis , ARN Viral/sangre , Proteínas Recombinantes , Estudios Retrospectivos , Ribavirina/administración & dosificación , Ribavirina/efectos adversos , Resultado del TratamientoRESUMEN
Age is one of the main factors involved in the rapidity and the magnitude of CD4(+) T cell repopulation in human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral treatment (HAART). Improved thymic function has been suggested as the main factor associated with CD4(+) T cell restoration after HAART. This work was undertaken to determine, among host factors, the predictor variable at baseline involved in the magnitude of short- and long-term recovery of CD4(+) T cells after HAART. HIV-RNA levels and CD4(+) T cell numbers were determined in 54 HIV-infected adults at baseline and at weeks 4, 12, 48 and 96 after HAART. T cell subpopulations were determined by flow cytometry, thymic volume by computed tomography, T cell receptor excision circle (TREC)-bearing cells by quantitative polymerase chian reaction (PCR) and interleukin (IL)-7 levels by enzyme linked immunosorbent assay at baseline. The phenotype of patients' isolates was determined by infecting GHOST cells expressing CCR5 and CXCR4. The possible interference of phenotype with thymic function was also analysed. Baseline thymic volume was associated independently with the magnitude of short- and long-term recovery of CD4(+) T cells after HAART, despite the patients' viral phenotype. The measurement of thymic volume before therapy may predict the magnitude of T cell increase. This result could have important clinical implications not only in HIV-infected patients, but also in other scenarios of T cell depletion such as bone marrow transplantation and chemotherapy.
Asunto(s)
Linfocitos T CD4-Positivos/inmunología , Infecciones por VIH/diagnóstico por imagen , Infecciones por VIH/inmunología , VIH-1 , Timo/diagnóstico por imagen , Adulto , Fármacos Anti-VIH/uso terapéutico , Terapia Antirretroviral Altamente Activa , Femenino , Infecciones por VIH/tratamiento farmacológico , VIH-1/genética , Hepatitis C/complicaciones , Hepatitis C/inmunología , Humanos , Recuento de Linfocitos , Masculino , ARN Viral/análisis , Timo/inmunología , Tomografía Computarizada por Rayos X , Carga ViralRESUMEN
An important thymus role has been suggested in T-cell repopulation after HAART in adult HIV-1 infected patients. Thymus volume increase after treatment has been described in HIV-1 infected children but not in adult patients. The objective of this work was to evaluate the effect of HAART on the thymic volume of adult HIV-1 infected patients and its relation with the T-cell repopulation. Twenty-one adult patients following 24 weeks under HAART were included in the study. All patients underwent a thoracic computed tomography (CT) evaluation for the measurement of thymic volumes at weeks 0, 12 and 24. Baseline thymus volume showed a significant correlation with the patient's age. Thymic volume significantly increased after 24 weeks of HAART. Besides, a significant correlation between changes in the thymus volume and changes in both total and naïve CD4+ cell counts was found. Only patients with increases > or =100 CD4+ cell counts after treatment significantly increased the thymic volume. These data show the first evidence of an early change in thymic volume of adult HIV-1 infected patients under HAART. This increase was related to the rise of both total and naïve CD4+ cell counts suggesting a functional role of thymic volume increase.
Asunto(s)
Terapia Antirretroviral Altamente Activa , Recuento de Linfocito CD4 , Infecciones por VIH/patología , VIH-1 , Subgrupos de Linfocitos T/inmunología , Timo/patología , Adulto , Factores de Edad , Femenino , Infecciones por VIH/tratamiento farmacológico , Humanos , Masculino , Tamaño de los Órganos , Timo/diagnóstico por imagen , Tomografía Computarizada por Rayos X , Carga ViralAsunto(s)
Infecciones por VIH/complicaciones , Hepatitis C Crónica/complicaciones , Fármacos Anti-VIH/administración & dosificación , Fármacos Anti-VIH/uso terapéutico , Terapia Antirretroviral Altamente Activa , Antivirales/administración & dosificación , Antivirales/uso terapéutico , Biopsia , Quimioterapia Combinada , Femenino , Predicción , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/virología , Hepatitis C Crónica/tratamiento farmacológico , Hepatitis C Crónica/patología , Hepatitis C Crónica/virología , Humanos , Interferones/administración & dosificación , Interferones/uso terapéutico , Hígado/patología , Masculino , Embarazo , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Ribavirina/administración & dosificación , Ribavirina/uso terapéutico , Factores de Riesgo , Carga ViralRESUMEN
The effect of vaccinating patients with sustained undetectable HIV-1 viremia (VL) achieved with highly active antiretroviral therapy was prospectively investigated. During the 1998 influenza immunization period, 39 HIV-1-infected patients who showed a VL<20 copies/ml for at least 6 months before the study entry date were vaccinated for influenza. Twenty-two vaccinees were immunized at entry. Seventeen controls were followed for 4 weeks after entry, crossing over then to the vaccination group. The proportion of patients with undetectable VL was not significantly different between the vaccination and control groups 2 and 4 weeks after entry. Therefore, influenza immunization of patients with undetectable viremia achieved with highly active antiretroviral therapy does not seem to affect VL.
Asunto(s)
Terapia Antirretroviral Altamente Activa , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/inmunología , VIH-1/inmunología , Vacunas contra la Influenza/administración & dosificación , Viremia/inmunología , Adulto , Estudios Cruzados , Femenino , Infecciones por VIH/sangre , VIH-1/efectos de los fármacos , VIH-1/genética , Humanos , Masculino , Estudios Prospectivos , ARN Viral/sangre , Carga Viral , Viremia/tratamiento farmacológico , Replicación Viral/efectos de los fármacosRESUMEN
OBJECTIVES: Some HIV-1 infected patients show low levels of viraemia despite having advanced immunosuppression. Cases with falsely undetectable viraemia by conventional PCR have been reported when patients were infected with non-B subtypes. The aim of this study was to investigate whether this immunovirological discordance can be due to the presence of HIV-1 non-B subtypes, and whether a modified PCR procedure can yield different HIV viraemia values in these cases. METHODS: Fifteen HIV-infected patients either naive for antiretroviral drugs or under treatment, with HIV plasma viraemia below 1000 copies/mm(3)and CD4+ cell counts lesser than 500 or 300 cells/mm(3), respectively, were included. Serotyping, genotyping and HIV plasmatic viraemia determinations were performed in all individuals. RESULTS: In five out of six treatment-naive patients the virus was categorized as non-B subtype by serotyping, although only one case was confirmed by genotyping as HIV-2. Eight out of nine patients under antiretroviral therapy were subtype B carriers by serotyping and confirmed by genotyping. The remaining patient was determined as a subtype A carrier by both procedures. A modified PCR procedure (Amplicor HIV Monitor Test version 1.5) did not yield higher viral load levels than the former version. CONCLUSIONS: The presence of HIV-1 subtypes non-B can explain a minority of cases of this immunovirological discordance, but in most of them the reason is still unknown. Likewise, a PCR procedure adapted for detecting HIV-1 non-B subtypes fails to find higher plasma viraemia in patients with such a discordance.
Asunto(s)
Infecciones por VIH/virología , VIH-1/clasificación , Tolerancia Inmunológica , Carga Viral , Viremia/virología , Adulto , Recuento de Linfocito CD4 , Estudios de Cohortes , Femenino , Genotipo , Infecciones por VIH/inmunología , VIH-1/genética , VIH-1/fisiología , Humanos , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa/métodos , Serotipificación , Viremia/diagnóstico , Viremia/inmunologíaRESUMEN
Seventeen human immunodeficiency virus-infected patients who were harboring untreated subclinical visceral leishmaniasis (VL) were prospectively followed up. None of the 11 patients who received highly active antiretroviral therapy (HAART) presented with symptomatic VL during follow-up, whereas 2 out of 6 patients who received therapy other than HAART had an episode of overt kala-azar. These findings suggest that HAART does not induce the evolution of latent VL into symptomatic disease.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/fisiopatología , Terapia Antirretroviral Altamente Activa , Infecciones por VIH/tratamiento farmacológico , Leishmaniasis Visceral/fisiopatología , Adulto , Femenino , Infecciones por VIH/complicaciones , Humanos , MasculinoRESUMEN
BACKGROUND/AIMS: The rate of progression to cirrhosis of chronic hepatitis C might be related to an upregulation of TNF-alpha/Fas pathways. METHODS: The serum levels of soluble TNF-alpha type II receptor (sTNFr-II) and soluble Fas antigen (sFas) were analyzed in patients with different histological outcomes of chronic parenterally acquired HCV infection of similar duration. RESULTS: One hundred and forty-five HCV-infected patients had a known duration of infection. Twelve (8.3%) patients had minimal changes and were assigned to the case group. The control group was selected from the 24 (17%) patients with cirrhosis and the 54 (37%) with chronic active hepatitis (CAH). Two controls, one with CAH and one with cirrhosis, were paired with the cases following these criteria: duration of infection, transmission route and sex. The proportions of genotype 1b and HCV RNA serum levels were similar among the groups. The median serum levels of sTNFr-II and sFas were significantly lower in the case group than in the control groups. The cases were significantly younger when they became infected than the control groups. Indeed, most cases were infected within the first 10 years of life. sTNFr-II and age at infection were independently associated with the minimal injury case group. When sTNFr-II was excluded from the logistic regression model, sFas and age at infection were independently associated with the case group. CONCLUSION: The rate of progression of parenterally acquired chronic hepatitis C to end-stage liver disease might be related to an upregulation of the TNF-alpha/Fas pathways and an age-dependent host response.
Asunto(s)
Antígenos CD/sangre , Hepatitis C Crónica/sangre , Cirrosis Hepática/sangre , Receptores del Factor de Necrosis Tumoral/sangre , Receptor fas/sangre , Adolescente , Adulto , Edad de Inicio , Niño , Preescolar , Progresión de la Enfermedad , Femenino , Hepacivirus/genética , Hepacivirus/aislamiento & purificación , Hepatitis C Crónica/complicaciones , Hepatitis C Crónica/patología , Humanos , Lactante , Hígado/patología , Hígado/virología , Cirrosis Hepática/patología , Cirrosis Hepática/virología , Masculino , ARN Viral/sangre , Receptores Tipo II del Factor de Necrosis TumoralRESUMEN
The aim of this work was to analyze the effects of highly active antiretroviral therapy on the chronically activated immune system of 26 antiretroviral-naive HIV-1-infected patients. Samples from baseline to week 24 or 36 of treatment were tested for serum levels of beta2-microglobulin, tumor necrosis factor alpha and soluble tumor necrosis factor alpha receptor type II, as well as for human leukocyte antigen-DR expression on T cells. After starting therapy, the mean HIV-1 RNA serum levels decreased and the mean CD4 + cell counts increased from baseline to week 36 (P< 0.001). Mean levels of tumor necrosis factor alpha receptor type II, tumor necrosis factor alpha and beta2-microglobulin as well as expression of human leukocyte antigen-DR were significantly reduced at the end of follow-up (P<0.01). Deactivation kinetics of these parameters was similar in patients with CD4+ counts>200 cells/microl at baseline versus those with CD4 + counts < 200 cells/microl at baseline, despite higher activation at baseline in the group with <200 cells/microl. In summary, this study shows that highly active antiretroviral therapy is able to induce a strong deactivation of the immune system of HIV-1-infected patients.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Fármacos Anti-VIH/uso terapéutico , VIH-1 , Síndrome de Inmunodeficiencia Adquirida/inmunología , Adulto , Antígenos CD/sangre , Femenino , Antígenos HLA-DR/análisis , Humanos , Masculino , Receptores del Factor de Necrosis Tumoral/sangre , Receptores Tipo II del Factor de Necrosis Tumoral , Factor de Necrosis Tumoral alfa/análisis , Microglobulina beta-2/sangreRESUMEN
Organic pentavalent antimonials are one of the mainstays of treatment for visceral leishmaniasis (VL). Few data are available on the toxicity and efficacy of these drugs at the dosing schedule recommended by the Centers for Disease Control and Prevention (CDC) (Atlanta, GA). We analyzed 25 VL episodes in human immunodeficiency virus (HIV)-infected patients who were treated with meglumine antimoniate (MA) at the CDC-recommended dose in southern Spain. Adverse effects were observed in 14 (56%) VL episodes. In 7 (28%), treatment with MA was permanently discontinued due to serious adverse effects that included acute pancreatitis, acute renal failure, and leukopenia. Three (12%) patients died during therapy due to severe acute pancreatitis attributable to MA. The dosing regimen of MA currently recommended for treating VL is associated with a high rate of serious side effects in HIV-1-infected patients.
Asunto(s)
Antiprotozoarios/efectos adversos , Infecciones por VIH/complicaciones , VIH-1 , Leishmania infantum/efectos de los fármacos , Leishmaniasis Visceral/tratamiento farmacológico , Meglumina/efectos adversos , Compuestos Organometálicos/efectos adversos , Adulto , Amilasas/sangre , Animales , Antimonio/administración & dosificación , Antimonio/efectos adversos , Antimonio/uso terapéutico , Antiprotozoarios/administración & dosificación , Antiprotozoarios/uso terapéutico , Médula Ósea/parasitología , Creatinina/sangre , Femenino , Humanos , Leishmaniasis Visceral/complicaciones , Recuento de Leucocitos , Masculino , Meglumina/administración & dosificación , Meglumina/uso terapéutico , Antimoniato de Meglumina , Compuestos Organometálicos/administración & dosificación , Compuestos Organometálicos/uso terapéutico , Pancreatitis/inducido químicamente , Recurrencia , Estudios Retrospectivos , VómitosRESUMEN
HIV-1 infected patients frequently develop opportunistic diseases involving the liver, particularly individuals with AIDS. Nevertheless, the role of liver biopsy (LB) in these patients is controversial. The prevalence of AC in seropositive subjects and the value of LB in patients with AC was investigated. The prevalence of AC in all outpatients attended at our Unit for a three month period was 2/119 (1.6%), whereas it was 20/66 (30.3%) for inpatients for a nine month period. LB was proposed to all patients with AC but not to those with a Karnofski index < 50 and those with an ethanol intake > 80 g per day. LB was performed in 16 patients, four were excluded, and 2 refused the procedure. Among symptomatic patients, LB: a) confirmed a previous diagnosis in six patients (40%); b) showed findings of nonspecific cholangitis in four cases (27%), and c) disclosed a previously unsuspected or unconfirmed disease in five patients (33%). LB is an useful diagnostic tool for the diagnosis of seropositive patients with AC, although a previous opportunistic event may account for symptoms and the corresponding enzymatic patterns.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/complicaciones , Colestasis/etiología , VIH-1 , Fosfatasa Alcalina/sangre , Biopsia , Colangitis/diagnóstico , Colestasis/diagnóstico , Colestasis/patología , Pruebas Enzimáticas Clínicas , Diagnóstico Diferencial , Humanos , Estado de Ejecución de Karnofsky , Hígado/patología , Masculino , Prevalencia , gamma-Glutamiltransferasa/sangreRESUMEN
Serum cytokine levels and peripheral T cell subpopulations of HIV-1-infected patients before, during and after active visceral leishmaniasis (VL) were analysed and compared with appropriate controls. At VL diagnosis, co-infected patients showed higher serum levels of interferon-gamma (IFN-gamma) than matched HIV-1 controls without VL, and lower serum concentrations of IL-10 than non-immunocompromised VL controls. High levels of tumour necrosis factor-alpha (TNF-alpha) and IFN-gamma were present in the sera of HIV-1-infected patients with active VL. TNF-alpha remained elevated after VL recovery. A steady decline in the CD4+ cell count, an increase of serum HIV viraemia and a progressive seroconversion for the HIV-1 p24 antigen was observed during the course of VL disease. Thus, an aberrant activation of the TNF system with possible negative immunological and virological consequences is present in HIV-1-infected patients with VL. A more extensive prospective validation of these findings in a bigger cohort of patients will nevertheless be necessary. The results support the hypothesis that different opportunistic infection agents may trigger the production of proinflammatory cytokines during immunodeficiency, and in this way accelerate the course of HIV-1 disease.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/inmunología , VIH-1/inmunología , Interferón gamma/sangre , Interleucina-10/sangre , Leishmaniasis Visceral/inmunología , Factor de Necrosis Tumoral alfa/análisis , Adulto , Línea Celular , Femenino , VIH-1/genética , Humanos , Leishmaniasis Visceral/complicaciones , Masculino , Estudios RetrospectivosRESUMEN
BACKGROUND: The objective of the present study was to investigate the relationship between the serum cytokine pattern of T-helper (Th) response and the acquisition of syncytium-inducing (SI) human immunodeficiency virus type 1 (HIV-1) variants in HIV-1-seropositive patients treated with antiretroviral drugs. METHODS: Serum cytokines of Th1/Th2 responses were analysed in a case-control study of 20 individuals selected from a cohort of HIV-1-infected patients without SI variants at entry, who developed or did not develop SI virus during a prospective follow-up. A group of 10 patients with SI variants at study entry was also evaluated. Serum concentration of interferon (IFN) gamma, interleukin (IL) 2, IL-4 and IL-10 was evaluated by mean of a commercial enzyme immunoassay. RESULTS: Despite close matching for immunological (CD4+ cell count) and virological (p24 antigen, serum HIV viraemia) parameters, SI-converting patients showed at baseline significantly lower serum levels of IL-2 and higher concentrations of IL-4 than those who remained persistently negative for SI variants. Shortly after the phenotype conversion, SI-converting patients were characterized by significantly high serum concentration of IL-4 and by low levels of IFN-gamma (Th2-like pattern). Patients with SI phenotype at study entry featured lower mean levels of both IL-4 and IL-10, but mean IFN-gamma and IL-2 values were higher, although the clinical and immunological baseline was also poorer and no statistical analysis could be applied. CONCLUSION: Serum cytokine pattern of Th1/Th2 response differs between patients with NSI and SI phenotype. Our data strongly suggest that the Th2 cytokine pattern could be associated with the acquisition of the SI HIV-1 phenotype.
Asunto(s)
Citocinas/sangre , Células Gigantes/patología , Infecciones por VIH/inmunología , VIH-1/inmunología , VIH-1/patogenicidad , Células Th2/inmunología , Estudios de Casos y Controles , Efecto Citopatogénico Viral , Infecciones por VIH/sangre , Infecciones por VIH/patología , Humanos , Interferón gamma/sangre , Interleucina-10/sangre , Interleucina-2/sangre , Interleucina-4/sangre , FenotipoRESUMEN
The actual prevalence of visceral leishmaniasis among human immunodeficiency type 1 (HIV-1)-infected patients in the Mediterranean basin remains unknown. There is also controversy about the risk factors for Leishmania infantum and HIV-1 coinfection. To appraise the prevalence of visceral leishmaniasis in patients infected with HIV-1 in southern Spain and to identify factors associated with this disease, 291 HIV-1 carriers underwent a bone marrow aspiration, regardless of their symptoms. Giemsa-stained samples were searched for Leishmania amastigotes. Thirty-two (11%) patients showed visceral leishmaniasis. Thirteen (41%) patients had subclinical cases of infection. Centers for Disease Control and Prevention (CDC) clinical category C was the factor most strongly associated with this disease (adjusted odds ratio [OR], 1.88 [95% confidence interval, 1.22 to 2.88]), but patients with subclinical cases of infection were found in all CDC categories. Female sex was negatively associated with visceral leishmaniasis (adjusted OR, 0.42 [95% confidence interval, 0.18 to 0.97]). Intravenous drug users showed a higher prevalence than the remaining patients (13.3 versus 4.9%; P = 0.04), but such an association was not independent. These results show that visceral leishmaniasis is a very prevalent disease among HIV-1-infected patients in southern Spain, with a high proportion of cases being subclinical. Like other opportunistic infections, subclinical visceral leishmaniasis can be found at any stage of HIV-1 infection, but symptomatic cases of infection appear mainly when a deep immunosuppression is present. There is also an association of this disease with male sex and intravenous drug use.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/epidemiología , Infecciones Oportunistas Relacionadas con el SIDA/parasitología , Seropositividad para VIH/complicaciones , VIH-1 , Leishmania infantum , Leishmaniasis Visceral/epidemiología , Adolescente , Adulto , Anciano , Animales , Recuento de Linfocito CD4 , Portador Sano , Demografía , Femenino , Seropositividad para VIH/inmunología , Seropositividad para VIH/parasitología , Humanos , Leishmaniasis Visceral/complicaciones , Leishmaniasis Visceral/inmunología , Masculino , Persona de Mediana Edad , Prevalencia , España/epidemiologíaAsunto(s)
Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/complicaciones , Infecciones por VIH/tratamiento farmacológico , VIH-1/genética , Hepacivirus/genética , Hepatitis C/complicaciones , Carga Viral , Hepacivirus/efectos de los fármacos , Hepatitis C/sangre , Humanos , ARN Viral/sangre , ViremiaRESUMEN
BACKGROUND: In recent years there has been a change in the opportunistic diseases incidence in HIV-infected patients. The change could be related to the use antiviral therapy and chemoprophylaxis strategies. The aim of the present study was to evaluate if medical intervention is able to modificate the clinical presentation of AIDS and the CD4+ lymphocyte counts at time of AIDS diagnosis. PATIENTS AND METHODS: The first AIDS-defining condition and the CD4+ count at time of AIDS diagnosis were analyzed in 95 HIV-infected patients who developed an AIDS-defining disease since April 1989 until March 1996, retrospectively reviewed. Patients who had been previously followed at an AIDS Unit were compared with those who had not. RESULTS: The frequency of Pneumocystis carinii pneumonia as the first AIDS-defining condition was lower in medically followed patients. Among this group, AIDS cases who received chemoprophylaxis with isoniazide showed a decrease in the rate of tuberculosis. No differences were found in CD4+ lymphocyte counts between both groups. CONCLUSIONS: As a result of medical intervention significant changes have occurred in the spectrum of initial AIDS-defining conditions in relation to medical intervention; a decrease in the frequency of Pneumocystis carinii pneumonia and tuberculosis have been found; however, the CD4+ lymphocyte counts at time of AIDS diagnosis are not modificated by medical intervention.
Asunto(s)
Síndrome de Inmunodeficiencia Adquirida/diagnóstico , Infecciones Oportunistas Relacionadas con el SIDA/epidemiología , Síndrome de Inmunodeficiencia Adquirida/sangre , Adulto , Linfocitos T CD4-Positivos , Progresión de la Enfermedad , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Estudios RetrospectivosRESUMEN
The aims of this study were to analyze the mortality directly attributable to chronic viral hepatitis in HIV-1 infected patients and to investigate the influence of hepatitis virus infections on the survival of this population. A cohort of 328 HIV-1 infected, antiretroviral-treated patients, followed up from 1989 to 1996, was investigated in the study. The median follow-up period of the cohort was 120 weeks. The median baseline CD4 + cell count of the cohort was 303 cells/mm3. Hepatitis C virus, hepatitis B virus and hepatitis D virus infections were present in 214 (65%), 16 (4.9%) and 9 (2.7%) patients, respectively. Sixty-seven (20.4%) subjects died but there was no information on the vital status of 36 patients (11%). The causes of mortality were AIDS in 49 (73%), liver failure in 3 (4.5%) and other causes in 15 (22.4%). The cohort was divided into two groups for survival analysis, the groups consisting of persons infected by a hepatitis virus and persons without hepatitis virus infection. There was no difference in survival between the two groups (p = 0.31, log-rank). It is concluded that mortality among HIV-1/hepatitis virus coinfected patients with moderate to severe immunosuppression is mostly due to AIDS, and that the survival of these subjects is not influenced by the presence of hepatitis virus infections, particularly hepatitis C virus.
Asunto(s)
Fármacos Anti-VIH/uso terapéutico , Infecciones por VIH/complicaciones , Hepatitis C/complicaciones , Adulto , Recuento de Linfocito CD4 , Estudios de Cohortes , Femenino , Infecciones por VIH/tratamiento farmacológico , Infecciones por VIH/mortalidad , VIH-1 , Humanos , MasculinoRESUMEN
The relationship between serum concentration of different components of the nerve growth factor/tumor necrosis factor (TNF) receptor family, including soluble APO-1/Fas (sAPO-1/Fas) and progression of HIV infection, was analyzed in a case-control study of individuals selected from a cohort of HIV-seropositive patients who were progressing or not progressing to AIDS while being treated with nucleoside analogs. HIV-seronegative healthy controls were also analyzed. The results showed that, despite close matching for immunologic (CD4 cell count, beta2-microglobulin concentration) and virologic (p24 antigen, detection of HIV syncytium-inducing phenotype, plasma HIV viremia) parameters, the baseline serum concentrations of TNF-beta and sAPO-1/Fas were statistically different between progressing and nonprogressing patients. In addition, serum concentrations of TNF-beta and sAPO-1/Fas showed the strongest independent predictive power for progression to AIDS in a multivariate conditional logistic regression model. Because TNF-beta and Fas were suggested to be mediators of antigen-induced cell death (AICD) in HIV infection and sAPO-1/Fas was hypothesized to protect lymphocyte against AICD, these data suggest an important pathogenetic role for AICD in the progression of HIV infection.